Saliva samples collected from acutely infected hospitalized patients (n = 35, COV+), vaccinated recovered COVID-19 outpatients (n = 13, COV+ VAC+), and vaccinated infection naïve patient samples (n = 13, COV− VAC+) were assayed by EFIRM anti-RBD IgG/IgM/IgA. This evidence concerns the gene CD79A and COVID-19.